Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model

Abstract

Our results suggest that suboptimal dosing may facilitate resistance amplification in a high inoculum of E. coli. The clinical dose of moxifloxacin (400 mg/day) was adequate to suppress resistance development in three wild-type strains. Clinical relevance of these findings warrants further in vivo investigation.